Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ENLVBullishIndustry Newsnews

High materiality7/10

Enlivex Allocetra 12-Month Data Shows Durable Response, Near-Term Catalyst

Nov 2, 2026, 8:38 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive, durable 12-month efficacy signal supports upside; key driver is the November conference presentation, which could attract attention and trading interest despite the data being early-stage and subgroup-specific.

AI summary

What happened, with direct paths to the underlying reporting

Enlivex Ltd reports 12-month Allocetra data in patients aged 64+, showing 79.2% clinically meaningful response versus 47.6% placebo (p=0.027). The benefit persists after a single cycle and matches earlier 3- and 6-month results, suggesting a durable effect. Data will be presented at ACR Convergence on November 8, 2026, potentially catalyzing investor interest.

12-month Allocetra data in 64+ patients: 79.2% vs 47.6% placebo (p=0.027).
Durable response from a single Allocetra cycle aligns with 3- and 6-month data.
12-month results to be presented at ACR Convergence on Nov 8, 2026.
Nes-Ziona, Israel press release dated Nov 2, 2026 from Enlivex Ltd.
Potential near-term catalyst for ENLV if results replicate and gain attention.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Enlivex Allocetra 12-Month Data Shows Durable Response, Near-Term Catalyst

Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum